Cosmos Health's C-Sept PRO Antiseptic Hits $1.3M Annual Run Rate in Greek Hospitals
Event summary
- Cosmos Health's C-Sept PRO antiseptic solution achieved $108,000/month average sales over the past three months in Greek hospitals.
- Annualized sales projected to exceed $1.3M with ~72% gross margin.
- Product adopted across major public and private hospital groups in Greece.
- Repeat ordering pattern indicates durable demand in infection control.
The big picture
Cosmos Health is establishing a high-margin revenue stream in the infection control segment, leveraging its vertically integrated manufacturing and distribution capabilities. The Greek hospital market demonstrates strong adoption of proprietary antiseptic solutions with recurring demand patterns, positioning Cosmos to expand this model across Europe. With gross margins exceeding 70%, this product line could become a significant contributor to overall profitability.
What we're watching
- Market Expansion
- Whether Cosmos Health can replicate this success in additional European markets using its existing distribution network.
- Regulatory Compliance
- How the EMA-certified manufacturing platform will support scaling efforts across Europe.
- Revenue Stability
- The pace at which recurring hospital orders can drive predictable cash flow amid potential economic headwinds.
Related topics